CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Acorda Therapeutics Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Acorda Therapeutics Inc
TWO BLUE HILL PLAZA
Phone: (914) 347-4300p:914 347-4300 PEARL RIVER, NY  10965  United States Ticker: ACORACOR

Business Summary
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing therapies that restore function and enhance the lives of people with neurological disorders. The Company uses its ARCUS pulmonary delivery system, which is a technology platform designed to deliver medication through inhalation that is used in the development of a variety of inhaled medicines. The Company’s commercial products include INBRIJA (levodopa inhalation powder) and AMPYRA (dalfampridine). Inbrija is an inhaled levodopa (L-dopa) for intermittent treatment of OFF episodes, also known as OFF periods in people with Parkinson’s disease treated with carbidopa/levodopa regimen. Inbrija utilizes its ARCUS platform for inhaled therapeutics. AMPYRA (dalfampridine) is an extended-release tablet formulation of dalfampridine as a treatment to enhance walking in patients with multiple sclerosis (MS). Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYes--Yes

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Independent Chairman of the Board John P.Kelley 69 11/25/2019 12/1/2008
President, Chief Executive Officer, Director RonCohen 67 1/1/1995 1/1/1995
Chief Financial Officer MichaelGesser 60 11/8/2021 11/8/2021
6 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Biotie Therapies Corp Joukahaisenkatu 6 TURKU Finland
Biotie Therapies Corp (ADR) Joukahaisenkatu 6 TURKU Finland
Biotie Therapies Corp. (OLD) Joukahaisenkatu 6 TURKU Finland
BIOTIE 701 GATEWAY BLVD. SOUTH SAN FRANCISCO CA

Business Names
Business Name
ACOR
Acorda Therapeutics Ireland Limited
Acorda Therapeutics Limited
7 additional Business Names available in full report.

General Information
Number of Employees: 111 (As of 12/31/2022)
Outstanding Shares: 1,242,098 (As of 11/9/2023)
Shareholders: 11
Stock Exchange: NASD
Federal Tax Id: 133831168
Fax Number: (914) 347-4560


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, March 29, 2024